Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Regulatory changes are active now. Get notified before these peptides hit the market.
In February 2026, HHS announced that a wave of peptides previously restricted under Category 2 would move back toward Category 1 — eligible again for legal compounding by registered 503A/503B pharmacies. It’s the biggest regulatory shift the peptide industry has seen in over a decade. Below are 12of the most in-demand peptides we’re tracking through that process — status is tracked as announced, not yet final(the FDA’s official 503A bulk-substances list is still being finalized).
The FDA categorizes bulk drug substances (BDS) into three categories for compounding eligibility:
Category 1
Eligible for compounding. FDA has determined these substances can be safely compounded under current regulations.
Category 2
Under review. FDA is evaluating whether these substances should be permitted for compounding.
Category 3
Not eligible. FDA has determined these substances should not be compounded due to safety concerns.
The peptides listed below were named in the February 2026 reclassification announcement to move from Category 2 toward Category 1. Once the FDA finalizes a substance on the Category 1 (503A) list, compounding pharmacies can legally produce it after meeting manufacturing and testing requirements. Until the official list publishes, treat each status as announced/expected, not confirmed — and verify with the FDA or your pharmacist.
Named in the Feb 2026 reclassification — expected to return to legal compounding, pending the FDA’s official Category 1 list.
Healing / Recovery
Skin / Copper Peptide
Growth Hormone Secretagogue
Growth Hormone Secretagogue
Healing / Recovery
Growth Hormone Releasing
Growth Hormone Releasing
Growth Hormone Secretagogue
Growth Hormone Secretagogue
Sleep / Neuropeptide
Anxiolytic / Nootropic
Skin / Wound Healing
This page tracks publicly reported regulatory status — it is not legal or medical advice, and statuses can change. Verify current status with the FDA or a licensed pharmacist before acting.
We’ll email you the moment any Category 1 peptide becomes available from a verified compounding pharmacy. No spam. Unsubscribe anytime.
Pharmacies prepare manufacturing
503A and 503B pharmacies are now setting up production for Category 1 peptides, including sourcing active ingredients and establishing quality testing protocols.
Quality testing begins
Each batch must pass identity, purity, potency, endotoxin, and sterility testing before it can be dispensed.
Prescribers start ordering
Once available, prescribers can order compounded versions of these peptides for their patients through verified pharmacies.
We verify and list
Disclosed Labs will independently test early batches from compounding pharmacies and publish results for transparency.
Regulatory information is for informational purposes only. Not medical or legal advice. Consult qualified professionals for guidance.
Disclosed Labs